nCino Reports First Quarter Fiscal Year 2026 Financial Results 29-05-2025, 03:05

Founder Group Limited Regains Compliance with Nasdaq’s Minimum Bid Price Requirement 3-03-2026, 20:30

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00